Cariprazine and Ivosidenib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ivosidenib
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Ivosidenib (Tibsovo) can speed up an enzyme in your liver called CYP3A4. That same enzyme handles cariprazine (Vraylar) and its active forms. Because ivosidenib revs up that enzyme, it could change how much cariprazine is working in your body. The tricky part is that cariprazine relies on this enzyme both to become active and to be cleared, so the net effect isn't easy to predict.
This combination is generally not recommended, but please don't stop either medicine on your own. Your care team can look at the whole picture and decide the safest plan for you.
Mechanism: Ivosidenib is a CYP3A4 inducer; cariprazine is a CYP3A4 substrate whose active metabolites (desmethyl- and didesmethyl-cariprazine) are both formed and eliminated via CYP3A4.
- Direction/magnitude: Net effect on total active-moiety exposure is unclear and has not been formally studied because CYP3A4 governs both formation and clearance of the active metabolites.
- Evidence: Theoretical.
- Onset: Unspecified; enzyme induction is typically delayed (days to weeks).
- Management: Coadministration is not recommended. If unavoidable, monitor closely for altered antipsychotic efficacy or tolerability; individualize therapy in consultation with the prescriber.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
It is advised against giving cariprazine (a substrate of CYP3A4) together with a CYP3A4 inducer. The generation and clearance of cariprazine's active metabolites depend on CYP3A4. No assessment has been made of how CYP3A4 inducers influence cariprazine exposure, so the overall outcome remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Because this combination is generally not recommended, your prescriber may consider whether an alternative medication is a better fit for you.
- If both are needed, your team may monitor you more closely for any change in how well cariprazine is working or for new side effects, and your dose may be adjusted and individualized.
What you can do:
- Keep taking both exactly as prescribed unless your care team tells you otherwise.
- Tell your pharmacist or prescriber that you take both, and report any mood changes, unusual side effects, or worsening symptoms.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cariprazine and Ivosidenib together?
Ivosidenib can speed up the enzyme that processes cariprazine, and the overall effect is unpredictable, so this combination is generally not recommended. Keep taking both as prescribed and check with your pharmacist or doctor, who can adjust therapy or monitor you more closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Ivosidenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Ivosidenib interaction managed?
What your care team may do: Because this combination is generally not recommended, your prescriber may consider whether an alternative medication is a better fit for you. If both are needed, your team may monitor you more closely for any change in how well cariprazine is working or for new side effects, and your dose may be adjusted and individualized. What you can do: Keep taking both exactly as… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cariprazine or Ivosidenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Ivosidenib
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist